hat
Alok Srivastava, MD, FRACP, FRCPA, FRCP, te resevwa onorè pou konsiltasyon akademik nan Bayer, Novo Nordisk, Roche, ak Shire / Takeda. Li te kenbe pozisyon lidèchip kòm Prezidan Gene Terapi Task Force nan SSC nan ISTH la ak Prezidan nan Komite a Steering nan Azi Pasifik Emofili Gwoup Travay la. Srivastava te resevwa finansman rechèch nan Alnylam, Bayer, ak konte.
eng
Alok Srivastava, MD, FRACP, FRCPA, FRCP, has received honoraria for academic consulting from Bayer, Novo Nordisk, Roche, and Shire/Takeda. He has held leadership positions as Chair of Gene Therapy Task Force of SSC of the ISTH and Chair of the Steering Committee of the Asia Pacific Hemophilia Working Group. Dr. Srivastava has received research funding from Alnylam, Bayer, and Shire.